Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026
Rhea-AI Summary
Valion Bio (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod for Acute Radiation Syndrome and oncology supportive care, will report Q1 2026 financial results after market close on May 14, 2026.
Management will host a conference call and webcast, with a replay available on the investor website.
Positive
- None.
Negative
- None.
News Market Reaction – VBIO
In the May 11 session, VBIO gained 15.63%, reflecting a significant positive market reaction. Argus tracked a peak move of +20.0% during that session. Argus tracked a trough of -8.0% from its starting point during tracking. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | Facility opening | Positive | +2.0% | Opened Velocity Bioworks facility enabling domestic Entolimod™ manufacturing. |
| May 05 | Clinical funding update | Positive | -3.4% | NIAID to fully fund BLA-enabling in vivo Entolimod™ studies. |
| May 04 | Leadership appointment | Positive | -3.4% | Appointed new General Counsel to support legal and regulatory strategy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive operational and clinical news has seen mixed reactions, with one modest gain and two declines, indicating a tendency for the stock to sometimes sell off despite constructive developments.
Over early May 2026, Valion Bio reported several notable milestones. On May 6, it opened Velocity Bioworks, enabling end-to-end domestic Entolimod™ production, and the stock rose about 2%. On May 5, news that NIAID would fully fund BLA‑enabling in vivo studies up to $7 million coincided with a -3.35% move. A general counsel appointment on May 4 also saw a -3.35% reaction. Today’s earnings-date notice follows this stretch of mixed price responses to fundamentally positive updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Management will host a conference call and webcast to discuss the Company's financial results and provide a business update.
Conference Call and Webcast Details
Webcast: https://www.webcaster5.com/Webcast/Page/2865/54024
Dial-In: 888-506-0062
International: 973-528-0011
Participant Access Code: 118764
A replay of the webcast will be available on the Investors section of the Company's website following the conclusion of the event.
About Valion Bio, Inc.
Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod™, a TLR5 agonist, for Acute Radiation Syndrome (ARS), oncology supportive care, and longevity indications. Entolimod™ for ARS has received Fast Track and Orphan Drug designations from the
Forward-Looking Statements
This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other
Investor + Media Contact
Rich Cockrell
CG Capital
vbio@cg.capital
View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bio-to-report-first-quarter-2026-financial-results-on-may-14-2026-302767800.html
SOURCE Valion Bio, Inc.